why choose us

First received: November 10, 2022

Clinical Trial: Losartan to Reduce Radiation Induced Fibrosis in Breast Cancer Patients

Study Status: Completed

Recruit Status: RECRUITING

Condition: Radiation Induced Fibrosis

Study Type: INTERVENTIONAL


Official Title: A Pilot Study of Losartan to Reduce Radiation Induced Fibrosis in Breast Cancer Patients

Brief Summary: This study will evaluate the efficacy of Losartan (LOS), an FDA-approved transforming growth factor beta-1 (TGF-?1) blocker, to decrease radiation induced fibrosis (RIF) in the breast and the lung of breast cancer patients, testing the hypothesis that Losartan will decrease RIF, TGF- ?1 and cellular senescence/inflammation in the breast and the lung of irradiated breast cancer patients relative to placebo treatment and consequently improve clinical outcomes in breast cancer patients.

Read more